DE69825605T2 - Behandlung der schizophrenie und der psychose - Google Patents

Behandlung der schizophrenie und der psychose Download PDF

Info

Publication number
DE69825605T2
DE69825605T2 DE69825605T DE69825605T DE69825605T2 DE 69825605 T2 DE69825605 T2 DE 69825605T2 DE 69825605 T DE69825605 T DE 69825605T DE 69825605 T DE69825605 T DE 69825605T DE 69825605 T2 DE69825605 T2 DE 69825605T2
Authority
DE
Germany
Prior art keywords
schizophrenia
treatment
psychosis
rats
methylpyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69825605T
Other languages
German (de)
English (en)
Other versions
DE69825605D1 (de
Inventor
Frank Sams-Dodd
Arnt Jorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Application granted granted Critical
Publication of DE69825605D1 publication Critical patent/DE69825605D1/de
Publication of DE69825605T2 publication Critical patent/DE69825605T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69825605T 1997-05-29 1998-05-28 Behandlung der schizophrenie und der psychose Expired - Fee Related DE69825605T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK62097 1997-05-29
DK62097 1997-05-29
PCT/DK1998/000220 WO1998053820A1 (en) 1997-05-29 1998-05-28 Treatment of schizophrenia and psychosis

Publications (2)

Publication Number Publication Date
DE69825605D1 DE69825605D1 (de) 2004-09-16
DE69825605T2 true DE69825605T2 (de) 2005-09-15

Family

ID=8095640

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69825605T Expired - Fee Related DE69825605T2 (de) 1997-05-29 1998-05-28 Behandlung der schizophrenie und der psychose

Country Status (10)

Country Link
US (1) US6297262B1 (enExample)
EP (1) EP1014974B1 (enExample)
JP (1) JP2002500651A (enExample)
AT (1) ATE273007T1 (enExample)
AU (1) AU7639598A (enExample)
DE (1) DE69825605T2 (enExample)
ES (1) ES2227836T3 (enExample)
PT (1) PT1014974E (enExample)
WO (1) WO1998053820A1 (enExample)
ZA (1) ZA984633B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
ES2660765T3 (es) 2004-06-21 2018-03-26 The Board Of Trustees Of The Leland Stanford Junior University Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ES2534672T3 (es) 2005-11-12 2015-04-27 The Board Of Trustees Of The Leland Métodos relacionados con FGF2 para diagnosticar y tratar la depresión
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2875674A1 (en) 2012-06-05 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE845612A (fr) 1976-03-23 1977-02-28 Derives de tetrazole-5-carboxamide et leur preparation
DE3421072A1 (de) 1984-06-06 1985-12-12 Heinrich Mack Nachf., 7918 Illertissen 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ES2061502T3 (es) 1986-06-27 1994-12-16 Beecham Group Plc Nuevos n-heterociclos biciclicos puenteados.
IL83275A (en) 1986-09-08 1994-02-27 Novo Nordisk As Substituted 1, 2, 4- oxadiazolyl piperidine compounds, their preparation and pharmaceutical compositions containing them
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5405853A (en) 1987-09-10 1995-04-11 Merck Sharpe & Dohme Ltd. Thiadiazoles useful in the treatment of senile dementia
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5328925A (en) 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5073560A (en) 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
IE922270A1 (en) 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives
DE69332641T2 (de) 1992-08-31 2003-11-27 University Of Florida Research Foundation, Inc. Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
IL106877A (en) 1992-09-10 1998-03-10 Lilly Co Eli Rhodanine derivatives for use as medicaments for the treatment of alzheimer's disease
NZ336597A (en) 1993-08-19 2001-02-23 Novo Nordisk As Use of oxa- or thia-diazole substituted pyridines for treatment of schizophrenia
US5705512A (en) 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5691365A (en) 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
US5756501A (en) 1995-12-13 1998-05-26 American Home Products Corporation Saturated and unsaturated pyridazino 4,5-B! indolizines useful as antidementia agents
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA

Also Published As

Publication number Publication date
EP1014974A1 (en) 2000-07-05
WO1998053820A1 (en) 1998-12-03
ATE273007T1 (de) 2004-08-15
PT1014974E (pt) 2004-12-31
AU7639598A (en) 1998-12-30
JP2002500651A (ja) 2002-01-08
ZA984633B (en) 1998-12-11
ES2227836T3 (es) 2005-04-01
US6297262B1 (en) 2001-10-02
DE69825605D1 (de) 2004-09-16
EP1014974B1 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
DE69825605T2 (de) Behandlung der schizophrenie und der psychose
DE69625518T2 (de) Wirkstoff zur behandlung neurodegenerativer störungen
DE68903178T2 (de) Arylamido (und arylthioamido)-azabicycloalkane zur steigerung des erinnerungsvermoegens oder zur behebung von gedaechtnisschwaeche.
DE69507419T2 (de) Verwendung von einem Tetrahydropyridin- oder azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen
DE602004006895T2 (de) Verfahren zur behandlung von multipler sklerose
DE3786893T2 (de) Piperidinderivat zur Schmerzbehandlung.
EP0326023A2 (de) Benzamid gegen kognitive Erkrankungen
DE2552869A1 (de) Pharmazeutische zusammensetzungen mit piperidylindol-derivaten und deren herstellung
DE60212710T2 (de) Pharmazeutische zubereitungen enthaltend epothilone und deren verwendung bei der behandlung von karzinoid
DE69008853T2 (de) Verwendung eines Derivates des 1,3,7-Trimethylxanthins zur Behandlung von Gedächtnisstörungen, intellektuellen Störungen im Alter, und bei der Alzheimerkrankheit.
DE69103624T2 (de) Ipriflavone enthaltende pharmazeutische zubereitungen, verfahren zur herstellung und therapeutische verwendung.
DE69736180T2 (de) Behandlung von manischen erkrankungen
DE69117791T2 (de) 5-Aryl-4-alkyl-3H-1,2,4-triazol-3-thione zur Verbesserung des Gedächtnisses
DE69306990T2 (de) Physostigmin-Derivate, ihre Verwendung und sie enthaltende pharmazeutische Formulierungen
DE69330638T2 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
WO2000048599A1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE69907220T2 (de) Verwendung von substanz p antagonisten zur behandlung des chronischen ermüdungssyndroms und/oder der fibromyalgie
DE2224130C3 (de) Tryptophanderivate und sie enthaltende pharmazeutische Zubereitungen
DE3012837A1 (de) Analgetische und myotonolytische praeparate
DE60122252T2 (de) Verfahren zur behandlung von neurodegeneration
DE3779991T2 (de) Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen.
DE69708084T2 (de) Verwendung von pyridyl- und pyrimidyl-piperazinen zur herstellung eines medikaments zur behandlung von rauschgiftsbedingten beschwerden
DE2525064C2 (de) Arzneimittel mit Antiparkinson-Wirkung
DE60005526T2 (de) Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes
DE60307049T2 (de) Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee